Excess Cardiovascular Risk in Inflammatory Rheumatic Diseases: Pathophysiology and Targeted Therapy

Onat A., Direskeneli H.

CURRENT PHARMACEUTICAL DESIGN, cilt.18, sa.11, ss.1465-1477, 2012 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 18 Sayı: 11
  • Basım Tarihi: 2012
  • Doi Numarası: 10.2174/138161212799504740
  • Dergi Adı: CURRENT PHARMACEUTICAL DESIGN
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1465-1477
  • Anahtar Kelimeler: Anti-TNF therapy, cardiovascular diseases, disease-modifying anti-rheumatic drugs, HDL dysfunction, inflammation, lipoprotein(a), rheumatoid arthritis, HIGH-DENSITY-LIPOPROTEIN, SYSTEMIC-LUPUS-ERYTHEMATOSUS, APOLIPOPROTEIN-A-I, NECROSIS-FACTOR-ALPHA, C-REACTIVE PROTEIN, ACUTE MYOCARDIAL-INFARCTION, CONGESTIVE-HEART-FAILURE, INSULIN-RESISTANCE, ACCELERATED ATHEROSCLEROSIS, METABOLIC SYNDROME
  • Marmara Üniversitesi Adresli: Evet

Özet

The article reviews the evidence and extent of the excess cardiovascular risk in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and ankylosing spondylitis. RA entails nearly twice as high a standardized mortality ratio and is considered an equivalent of type 2 diabetes with regard to cardiovascular risk. The associated excess cardiovascular risk can only partly be explained by traditional risk factors, and the underlying inflammation is crucially involved in the pathogenesis.